181 related articles for article (PubMed ID: 11208833)
1. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
2. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
Terasawa T; Dahabreh IJ; Nihashi T
Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
[TBL] [Abstract][Full Text] [Related]
4. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis.
Zhu Y; Lu J; Wei X; Song S; Huang G
Biomed Res Int; 2013; 2013():275805. PubMed ID: 24288671
[TBL] [Abstract][Full Text] [Related]
6. Patients undergoing multiple
Indrakanti S; Li X; Rehani MM
Br J Radiol; 2022 Jul; 95(1135):20211225. PubMed ID: 35348374
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of CT‑based radiomics model of PET-negative residual CT masses: a potential biomarker for predicting relapse‑free survival in non-Hodgkin lymphoma patients showing complete metabolic response.
Cha SH; Kang KW; Han NY; Cho Y; Sung DJ; Park BJ; Kim MJ; Sim KC; Han YE; Sung HJ
Abdom Radiol (NY); 2024 Jan; 49(1):341-353. PubMed ID: 37884749
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic value of FDG-PET.
Geus-Oei LF; Oyen WJ
Cancer Imaging; 2008 Mar; 8(1):70-80. PubMed ID: 18390390
[TBL] [Abstract][Full Text] [Related]
9. Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.
Ferdinandus J; van Heek L; Roth K; Dietlein M; Eich HT; Baues C; Borchmann P; Kobe C
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):490-495. PubMed ID: 37735258
[TBL] [Abstract][Full Text] [Related]
10. Update on FDG-PET in pediatric lymphoma.
Kurch L; Kluge R
Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):58-69. PubMed ID: 38587361
[TBL] [Abstract][Full Text] [Related]
11. Progression of Myocardial 18F-FDG Uptake in a Patient with Cardiotoxicity.
Berenguer DRF; de Moraes Chaves Becker M; de Oliveira Buril R; Bertão PA; Markman Filho B; Brandão SCS
Arq Bras Cardiol; 2024; 121(2):e20230276. PubMed ID: 38422307
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.
Bailly C; Eugène T; Couec ML; Strullu M; Frampas E; Campion L; Kraeber-Bodéré F; Bodet-Milin C
Front Med (Lausanne); 2014; 1():54. PubMed ID: 25593926
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).
Wielenberg CF; Fostitsch JC; Volz C; Marks R; Michalski K; Wäsch R; Zeiser R; Ruf J; Meyer PT; Klein C
Nuklearmedizin; 2024 Apr; ():. PubMed ID: 38593856
[TBL] [Abstract][Full Text] [Related]
14. Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study.
Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A
Neuro Oncol; 2024 Feb; ():. PubMed ID: 38366824
[TBL] [Abstract][Full Text] [Related]
15. Baseline and early response 2-[18F]FDG-PET/MRI for prediction of radiotherapy outcome in uterine cervical squamous cell carcinoma: a prospective single-center observational cohort study.
Strandberg S; Jonsson J; Zarei M; Aglund K; Blomqvist L; Söderkvist K
EJNMMI Rep; 2024 Mar; 8(1):5. PubMed ID: 38748271
[TBL] [Abstract][Full Text] [Related]
16. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.
Ferrari C; Maggialetti N; Masi T; Nappi AG; Santo G; Niccoli Asabella A; Rubini G
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33803667
[TBL] [Abstract][Full Text] [Related]
17. Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma.
Figura N; Flampouri S; Mendenhall NP; Morris CG; McCook B; Ozdemir S; Slayton W; Sandler E; Hoppe BS
Adv Radiat Oncol; 2017; 2(2):197-203. PubMed ID: 28740932
[TBL] [Abstract][Full Text] [Related]
18. Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin's Lymphoma.
De Re V; Lopci E; Brisotto G; Elia C; Mussolin L; Mascarin M; d'Amore ESG; Aieop The Hodgkin's Lymphoma Research Network
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38275392
[TBL] [Abstract][Full Text] [Related]
19. Recurrent PET FDG Uptake after Sequential Chemotherapy and Radiation Therapy for DLBCL of the Tibia: A Case Report and Review of the Literature.
Miles EF; Balsamo L; Turton DB; Graf W
Case Rep Oncol Med; 2011; 2011():163472. PubMed ID: 22606440
[TBL] [Abstract][Full Text] [Related]
20. Aortic FDG Uptake in Patients With Cancer: An Imaging Biomarker of Susceptibility?
Divakaran S; Nohria A; Di Carli MF
JACC CardioOncol; 2020 Dec; 2(5):771-773. PubMed ID: 34396293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
